Price
No data yet.
Social Signal Score
Analyst Ratings
Company Profile
- CEO
- Miles Harrison
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 4
- Beta
- 0.51
- Country
- US
Quote
Valuation & Ratios
Returns & Efficiency
Valuation
CNXUhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70-30.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·5h ago·Negative
Conexeu Sciences Advances Ten Minute Tissue™ Toward Planned FDA 510(k) Submission RENO, Nev., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Conexeu Sciences Inc. (Nasdaq: CNXU) (“Conexeu” or the “Company”), a preclinical-stage medical device and regenerative medicine company advancing CXU™, an investigational tissue-restoration platform, today provided an update on the regulatory and manufacturing program supporting its planned U.S. Food and Drug Administration (“FDA”) 510(k) premarket notification for Ten …
View source ↗ - Newsglobenewswire.com·35d ago·Neutral
Conexeu Sciences Sets September and October 2026 Conference Schedule RENO, Nev., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Conexeu Sciences Inc. (Nasdaq: CNXU) (“Conexeu” or the “Company”), a preclinical-stage biotechnology company advancing an investigational tissue-restoration platform, is pleased to announce its participation in the following investor and industry conferences during September and October 2026.
View source ↗ - Newsglobenewswire.com·49d ago·Neutral
Conexeu Sciences Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration Peer-reviewed research points to the extracellular matrix, the framework that holds tissue together, as central to that work. More than a decade of research has gone into Conexeu's CXU™ Platform
View source ↗
Earnings
Typical surprise -95.0% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Sep 14$-0.29 vs $-0.10miss
- Mon, Jun 15$-0.11 vs $-0.11beat
Estimates and results for CNXU via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CNXU officers and directors.
- Bought
- $628k
- Sold
- —
2 trades
0 trades
- Purcell Lynn Sebastianbought
- Purcell Lynn Sebastianbought
39 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CNXU.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.